Comparison of umbilical cord blood transplantation and hematopoietic stem cell transplantation from HLA-matched sibling donors in the treatment of myelodysplastic syndrome-EB or acute myeloid leukemia with myelodysplasia-related changes.
10.3760/cma.j.issn.0253-2727.2019.04.006
- VernacularTitle:非血缘脐血干细胞移植与同胞造血干细胞移植治疗MDS-EB和AML-MRC的对比观察
- Author:
Jiang ZHU
1
;
Bao Lin TANG
;
Kai Di SONG
;
Xu Han ZHANG
;
Xiao Yu ZHU
;
Wen YAO
;
Xiang WAN
;
Hui Lan LIU
;
Zi Min SUN
Author Information
1. Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China.
- Publication Type:Journal Article
- Keywords:
Cord blood stem cell transplantation;
Hematopoietic stem cell transplantation;
Leukemia, myeloid, acute;
Myelodysplastic syndrome;
Survival analysis
- MeSH:
Adolescent;
Adult;
Cord Blood Stem Cell Transplantation;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute/therapy*;
Middle Aged;
Myelodysplastic Syndromes/therapy*;
Quality of Life;
Retrospective Studies;
Siblings;
Young Adult
- From:
Chinese Journal of Hematology
2019;40(4):294-300
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the clinical efficacy of umbilical cord blood transplantation (UCBT) and hematopoietic stem cell transplantation from HLA-matched sibling donors (MSD-HSCT) in the treatment of myelodysplastic syndrome-EB (MDS-EB) or acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) . Methods: A cohort of 64 patients (including 38 cases of MDS-EB and 26 cases of AML-MRC) who received UCBT/MSD-HSCT from February 2011 to December 2017 were retrospectively analyzed. Results: ①Compared with MSD-HSCT group, UCBT group had a higher proportion of AML-MRC patients [52.8% (19/36) vs 25.0% (7/28) , P=0.025], and a lower median age [13 (1.5-52) years vs 32 (10-57) years, P=0.001]. ②The engraftment of neutrophils both in UCBT and MSD-HSCT groups on +42 d was 100%, and the median engraftment time was 17.5 (11-31) d and 11.5 (10-20) d, respectively. The engraftment of platelet at +100 d in UCBT group was 91.4%, the median engraftment time was 40 (15-96) d; The engraftment of platelet at +100 d in MSD-HSCT group was 100%, and the median engraftment time was 15 (11-43) d. ③There were no statistically significant differences in terms of the cumulative incidence of Ⅱ-Ⅳ and Ⅲ/Ⅳ aGVHD of 100 d and transplant related mortality (TRM) of 180 d, relapse rate, overall survival (OS) , disease-free survival (DFS) between UCBT and MSD-HSCT groups (P>0.05) . ④The 3-year cumulative incidence of chronic GVHD (cGVHD) and severe chronic GVHD in UCBT group were lower than of MSD-HSCT group [28.3% (95%CI 13.4%-45.3%) vs 67.9% (95%CI 46.1%-82.4%) , P=0.002; 10.3% (95%CI 2.5%-24.8%) vs 50.0% (95%CI 30.0%-67.1%) , respectively, P<0.001]. The cumulative 3-year incidence of GVHD-free and relapse-free survival (GRFS) of UCBT group was significantly higher than of MSD-HSCT group [55.0% (95%CI 36.0%-70.6%) vs 28.6% (95%CI 13.5%-45.6%) , P=0.038]. Conclusion: UCBT could obtain better quality of life after transplantation than MSD-HSCT in treatment of MDS-EB/AML-MRC.
